Hawkins, Inc. — Form 10-Q Summary
Business context and period: Hawkins sells chemicals and specialty ingredients through its Industrial, Water Treatment, and Health and Nutrition segments. This report covers the second quarter and first six months of fiscal 2024, ended October 1, 2023; comparisons are to the corresponding periods ended October 2, 2022. Amounts below are in millions except per-share data.
Key financial results
| Metric | Q2 FY2024 | Q2 FY2023 | Six months FY2024 | Six months FY2023 |
|---|---|---|---|---|
| Sales | $236.5 | $241.2 | $487.6 | $487.7 |
| Gross profit | $53.9 | $46.4 | $105.9 | $93.1 |
| Gross margin | 22.8% | 19.2% | 21.7% | 19.1% |
| Operating income | $33.0 | $26.5 | $65.5 | $54.4 |
| Net income | $23.2 | $18.0 | $46.6 | $37.7 |
| Diluted EPS | $1.10 | $0.86 | $2.22 | $1.79 |
- Cash flow: Six-month operating cash flow was $92.6 versus $18.8 a year earlier. Investing used $19.9, including $16.9 of capital expenditures and $3.4 for the EcoTech acquisition. Financing used $69.3, including $52.0 of revolving-loan repayments, $9.8 of share repurchases, and $6.5 of dividends. Cash increased $3.4 to $11.0.
- Liquidity and debt: At October 1, cash was $11.0 and gross revolving-loan borrowings were $60.0 (reported debt net of issuance costs was $59.7), down from $112.0 gross at April 2. The $250 million revolving facility matures April 30, 2027; the company reported covenant compliance and said cash, facility availability, and operating cash flows should fund foreseeable operating needs. Effective borrowing rate was 3.0%; the company reported no unhedged variable-rate debt, with a $60 million interest-rate swap in place.
- Balance sheet: Total assets were $575.3, total liabilities $192.6, and shareholders’ equity $382.7. Inventory fell to $68.5 from $88.8 at fiscal year-end.
Material changes and operating drivers
- Quarterly sales declined 2%, while six-month sales were essentially flat. Water Treatment growth was offset by declines in Industrial and Health and Nutrition.
- Water Treatment sales rose 17% in Q2 and 18% for six months, reflecting higher selling prices and increased volume; six-month segment operating income increased to $36.4 from $21.7.
- Industrial sales declined 14% in Q2 and 8% for six months, reflecting lower volumes and the prior-year divestiture of consumer bleach packaging assets. Six-month operating income was $23.8 versus $24.4.
- Health and Nutrition sales declined 9% in Q2 and 12% for six months, primarily from weaker demand for distributed specialty products, customer excess inventory, and lower consumer demand for health and immunity products. Six-month operating income fell to $5.3 from $8.3.
- Gross-profit improvement included a $3.2 Q2 and $3.4 six-month benefit from lower LIFO reserves, mainly due to falling raw-material prices. The comparable prior-year periods had respective gross-profit reductions of $5.3 and $9.0 from rising raw-material prices. SG&A increased 6% in Q2 and 4% for six months, including higher variable compensation and acquired-business costs.
Outlook, risks, and other items
- Management expects a full-year effective tax rate of approximately 26%–27%. No revenue or earnings guidance was provided; management cautioned that first-half results are not necessarily indicative of full-year results.
- After quarter-end, Hawkins acquired Water Solutions Unlimited for $60 million plus up to $15 million contingent on targets, and Miami Products & Chemical Company for $15.5 million. Both are expected to be included in Water Treatment; purchase accounting was incomplete. EcoTech, acquired July 14 for $3.4 million, is included in Water Treatment from its acquisition date.
- Commodity chemical costs are cyclical. Hawkins seeks to pass cost changes to customers but cautioned it may not always be able to do so; it does not hedge commodity purchases. Bulk products are price-sensitive and generally carry lower margins.
- The company reported no material change in risk factors, no material pending legal proceedings, and effective disclosure controls as of quarter-end. It was in compliance with credit covenants and expected to remain compliant over the next 12 months.
Important facts for investors to verify
- Whether Water Treatment’s growth and improved per-unit margins persist, particularly after the two post-quarter acquisitions and their associated funding needs.
- How much earnings improvement reflects underlying operating performance versus LIFO reserve movements tied to raw-material price changes.
- Whether demand and margins in Health and Nutrition recover as customer inventory and consumer demand conditions change.
- How working-capital timing, commodity prices, and the company’s ability to pass through cost increases affect future operating cash flow and margins.
- Acquisition purchase-price allocation, contingent consideration terms and outcomes, and the effects on debt, liquidity, and covenant headroom.